- Prosensa Holding (RNA +1.3%) says it's begun dosing the first patient in its Phase I/II clinical trial of PRO053, a treatment for Duchenne muscular dystrophy.
- The trial is designed to assess the safety, efficacy, tolerability and pharmacokinetics of multiple doses of PRO053 in a subset of patients with the disease.
- The company says PRO053 induces exon 53 skipping and may be applicable to about 8% of all DMD patients.
Prosensa begins dosing first patient in Phase I/II trials of PR0053
Sep 6 2013, 10:40 ET